文献速递淋巴瘤血栓与止血

慢性淋巴细胞白血病患者新冠感染的临床结局与B/T细胞免疫:13个月连续病例分析

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
PubMed 文献 · Leukemia · 2021-09-25

77%住院,23%死亡,年龄≥75岁为唯一显著死亡风险因素;多数康复者产生持久B和/或T细胞免疫。

要点

  • CLL患者新冠住院率高达77%,死亡率23%,年龄≥75岁是唯一显著死亡风险因素。
  • 大流行后期(7-13月)死亡和ICU入住数值下降,但住院仍频繁。
  • 多数康复者产生持久中和抗体及SARS-CoV-2特异性T细胞免疫。

核心结论

  • CLL患者新冠感染仍导致高住院率,即使年轻早期患者亦如此。
  • 多数康复者产生稳健持久的B和/或T细胞免疫。
  • 年龄≥75岁是死亡的唯一显著风险因素。

研究设计与样本

  • 中位CIRS为8(范围4-20);38例惰性CLL,12例完成治疗,10例 ongoing 治疗。

主要发现

  • 14例(23%)死亡;年龄≥75岁为唯一显著风险因素(p<0.05,多因素分析效能有限)。
  • 比较1-6月与7-13月,死亡从32%降至18%,ICU入住从37%降至15%,住院仍频繁(86% vs 71%)。
  • 40例中33例(82%)血清转化;6个月和12个月分别17/22和8/11可检出抗SARS-CoV-2抗体。
  • 13/17有中和抗体,19/28唾液中有抗体;14/17患者ELISpot检测到SARS-CoV-2特异性T细胞。

临床怎么用

  • CLL患者感染新冠后应密切监测,尤其高龄患者死亡风险高。
  • 康复期应评估B和T细胞免疫,以指导防护和随访。

局限性

  • 多因素分析效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during month 1-13 of the pandemic. Sixty patients (median age 71 y, range 43-97) were identified. Median CIRS was eight (4-20). Patients had indolent CLL (n = 38), had completed (n = 12) or ongoing therapy (n = 10). Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 were admitted to ICU. Severe Covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except CIRS (p < 0.05). Fourteen patients (23%) died; age ≥75 y was the only significant risk factor (p < 0.05, multivariate analysis with limited power). Comparing month 1-6 vs 7-13 of the pandemic, deaths were numerically reduced from 32% to 18%, ICU admission from 37% to 15% whereas hospitalizations remained frequent (86% vs 71%). Seroconversion occurred in 33/40 patients (82%) and anti-SARS-CoV-2 antibodies were detectable at six and 12 months in 17/22 and 8/11 patients, respectively. Most (13/17) had neutralizing antibodies and 19/28 had antibodies in saliva. SARS-CoV-2-specific T-cells (ELISpot) were detected in 14/17 patients. Covid-19 continued to result in high admission even among consecutive and young early- stage CLL patients. A robust and durable B and/or T cell immunity was observed in most convalescents.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Blixt L, Bogdanovic G, Buggert M, et al. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia. 2021. PMID: 34564699. doi:10.1038/s41375-021-01424-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。